TickerFacts.

Evommune, Inc. (EVMN): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$76.68M
Year ended 2025-12-31
-$74.65M
Trailing 12 months to 2026-06-30
2024-12-31: -$58.28M2025-12-31: -$76.68M-$76.68M
2024-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$76.68Mn/m2026-03-05, From 2025-01-01
2024-12-31-$58.28Mn/a2026-03-05, From 2024-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Evommune, Inc. (EVMN)2025-12-31-$76.68Mn/m
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31-$103.21Mn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31-$12.0Kn/m
CV Sciences, Inc. (CVSI)2025-12-31-$516.0Kn/m
Pyxis Oncology, Inc. (PYXS)2025-12-31-$63.51Mn/m
Prelude Therapeutics Inc (PRLD)2025-12-31-$56.37Mn/m
Arbutus Biopharma Corp (ABUS)2025-12-31-$39.64Mn/m
Jaguar Health, Inc. (JAGX)2024-12-31-$29.40Mn/a
Crescent Biopharma, Inc. (CBIO)2025-12-31-$72.45Mn/m

Compare EVMN, TNXP, EMMA, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗